Trump considers reclassifying cannabis to Schedule III, a move that divides Republican leadership and comes as states adjust taxes, raise fees, and crack down on unsafe products, signaling regulatory realignment and uneven market pressures.
The MedCanG draft would tighten telemedicine rules and could limit access to cannabis flower in pharmacies, prompting pharmacists, patient groups, and parts of the coalition to warn of reduced access and a likely resurgence of black-market channels.
The TGA launches a public consultation on unapproved medical cannabis products, signaling tighter oversight aimed at improving quality and safety while balancing broad patient demand.
Legal cannabis contributed $76.5B to GDP as major operators reported profits and export growth, highlighting a mature domestic market with expanding international reach.
U.K. regulators advanced thousands of novel food CBD applications and confirmed the ban on HHC, while support for decriminalization in Guernsey grew—together outlining a more defined but cautious path for medical and low-THC access.
The government faces a September 30 deadline to regulate cultivation as the Parliamentary Cannabis Front pressures Anvisa.
Medical cannabis prescriptions and sales continue to rise, with prices lower than the illicit market; a new high-THC strain arrives.
The draft Cannabis Products Act proposes a strictly regulated non-medical market under consultation until December 2025.
The national cannabis experiment moves to regulated-only products, ending the grace period for illicit hash and forcing full alignment with legal supply chains.
With the Master Plan stalled, South Africa’s cannabis scene is driven by clubs, counterfeits, prisons, and research.